Cat. No.
MABL-3863
Application
Block, IF
Isotype
Engineer antibody
Species Reactivity
Mouse
Clone No.
9D9
From
Recombinant Antibody
Specificity
The antibody is specific for CTLA-4.
Alternative Names
CD152; CTLA4; Cytotoxic T-Lymphocyte Associated Protein 4; Insulin- Dependent Diabetes Mellitus 12; Celiac Disease 3; Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4; Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Fo
UniProt
P09793
Immunogen
The antibody was raised against CTLA-4.
Application Notes
The antibody has been used to block CTLA-4 and has been shown to enhance T-cell immunity against tumours (Quezada et al, 2006). 9D9 also has an anti-B16/BL6 melanoma effect in non- irradiated tumour-bearing recipients when given as combinatorial therapy with Gvax (Peggs et al, 2009). Selby et al. (PMID: 24777248) show how conversion of the original mouse IgG2b to a mouse IgG2a greatly increases anti-tumor activity of the 9D9 antibody in both MC38 (C57BL/6 mice) and CT26 (BALB/c mice) models. This mechanism both involves blockade of CTLA4 as well as depletion of tumor-infiltrating regulatory T-cells. Fc Silent antibodies were shown to have reduced anti-tumor activity as they did not deplete tumor infiltrating regulatory T-cells, however they lead to expansion of peripheral Tregs.
Antibody First Published
Simpson T et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma J Exp Med. 2013 Aug 26; 210(9): 1695–1710. PMID:23897981
Note on publication
Describes the characterisation of the Fcγ receptor-dependent activity of 9D9 on the T reg cell compartment.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
![Anti-Beta-galactosidase [13R4]](/public/static/common/images/not_adv.jpg)
